A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects with Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study

2024-512515-45-01 Protocol TBBO8520-101 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 10 Apr 2026 · Status Ongoing, recruiting · 2 EU/EEA countries · 9 sites · Protocol TBBO8520-101

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 269
Countries 2
Sites 9

Non-Small Cell Lung Cancer

Key facts

Sponsor
Theras Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
10 Apr 2026 → ongoing
Decision date (initial)
2026-03-12
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Non-Small Cell Lung Cancer

VersionLevelCodeTermSystem organ class
21.1 PT 10061873 Non-small cell lung cancer 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Theras Inc.

Sponsor organisation
Theras Inc.
Address
3160 Porter Drive Suite 250
City
Palo Alto
Postcode
94304-1222
Country
United States

Scientific contact point

Organisation
Theras Inc.
Contact name
CTIS Contact point

Public contact point

Organisation
Theras Inc.
Contact name
CTIS Contact point

Locations

2 EU/EEA countries · 9 investigational sites

By country

CountryMS statusPlanned subjectsSites
Denmark Ongoing, recruiting 5 1
Spain Ongoing, recruiting 40 8
Rest of world
Canada, Australia, United States
224

Investigational sites

Denmark

1 site · Ongoing, recruiting
Rigshospitalet
Department of Oncology, Phase I Unit, Blegdamsvej 9, 2100, Copenhagen Oe

Spain

8 sites · Ongoing, recruiting
Hospital Clinico Universitario De Valencia
Oncology, Avenida Blasco Ibanez 17, 46010, Valencia
Hospital Universitari Vall D Hebron
Oncology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Universitario Fundacion Jimenez Diaz
Oncology, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Hm Nou Delfos
Oncology, Avinguda De Vallcarca 151, 08023, Barcelona
Hospital Universitario Quironsalud Madrid
Oncology, Calle De Diego De Velazquez 1, 28223, Pozuelo De Alarcon
Hospital Beata Maria Ana
Oncology, Calle Del Doctor Esquerdo No. 83, 28007, Madrid
Institut Catala D'oncologia
Oncology, Avinguda De La Gran Via De L'hospitalet 199-203, 08908, L'hospitalet De Llobregat
Hospital General Universitario Gregorio Maranon
Oncology, Calle Del Doctor Esquerdo 46, 28007, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Denmark 2026-04-15 2026-04-24
Spain 2026-04-10 2026-04-16

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2026-01-12 Denmark Acceptable
2026-02-20
2026-03-12